Retinal Vein Occlusion is blockage of one of the retinal veins, which are blood vessels that carry deoxygenated blood back to the heart. Central retinal vein occlusion (CRVO) is a blockage in the main vein of your retina and Branch retinal vein occlusion (BRVO) occurs when the blockage is in a smaller branch of veins throughout the retina.

Retinal Vein Occlusion caused by glaucoma, which is a condition that damages the optic nerve, smoking, rare blood disorders, atherosclerosis, or hardening of the arteries and blood clots, which often travel from elsewhere in the body to the eye.

Signs and symptoms of Retinal vein occlusion includes blurry or missing vision in part or all an eye, dark spots or lines floating in vision, pain and pressure in the eye.

Doctors most often diagnose Retinal vein occlusion by using optical coherence tomography (OCT) to take a high-definition image of your retina, an instrument called an ophthalmoscope can be used to examine your retina and a fluorescein angiography which is a dye injected into a certain vein in your arm.

The most common investigative treatments of Retinal vein occlusion include antivascular endothelial growth factor (anti-VEGF) drugs which are injected into the eye, corticosteroid drugs that are injected into your eye to control the swelling.

The pipeline of Retinal Vein Occlusion treatment market consists of a great variable of drugs. Vascular Endothelial Growth Factor-A (VEGF-A) Inhibitors, Vascular Endothelial Growth Factor-B (VEGF-B) Inhibitors, Placental 1 Growth Factor (P1GF) Inhibitors and some others are the most highlighted class of this indication. Ongoing research and current trials have the potential to change the market.

More than 10 key players, including pharma giants such as ANBITION Srl, Allgenesis Biotherapeutics Inc, F. Hoffmann-La Roche Ltd and others are working to bring novel therapies that overcome the roadblocks of AML treatment pipeline.

Report Highlights

Global Insight Service’s, “Retinal Vein Occlusion – Drug Pipeline Landscape, 2023,” an overview of the Retinal Vein Occlusion pipeline drugs. This report covers detailed insights on Retinal Vein Occlusion drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to gain insights and thus help industry participants for decision making. Retinal Vein Occlusion pipeline report helps gaining insights on drugs which are under development stage of drug development process across globally. Global Insight Services aims to cover all the drug attributes, deals, regulatory milestones and all the upcoming milestones.

Recent Developments

In September 2021, Allgenesis Biotherapeutics Inc entered into a licensing agreement with AffaMed Therapeutics for the development and commercialization of AG-73305 for treating diabetic macular edema (DME), neovascular age-related macular degeneration (nAMD), and other retinal diseases such as retinal vein occlusion (RVO) in Greater China, South Korea, and multiple ASEAN markets.

In May 2022, EyePoint Pharmaceuticals Inc entered into license agreement with Betta Pharmaceuticals Co Ltd to develop and commercialize EYP-1901 in China, Hong Kong, Macau and Taiwan.

In December 2020, Asclepox Therapeutics Inc received the Investigational New Drug Application (IND) clearance from the US FDA for the treatment of retinal vein occlusion (RVO).

Key Products

BA9101 (Aflibercept, LY09004) is under development for the treatment of macular edema following retinal vein occlusion (RVO). In October 2020, Luye Pharma Group announced that Shandong Boan Biotechnology Co., Ltd. entered into a collaboration and exclusive promotion agreement with Ocumension Therapeutics Co., Ltd. to co-develop and commercialise Boan Biotech’s biopharmaceutical drug LY09004 in the mainland of China.

DrugsCompanyPhase Molecule TypeMoARoA
DrugsCompanyPhase Molecule TypeMoARoA
BA9101Luye Pharma Group LtdPhase IIIFusion ProteinVascular Endothelial Growth Factor-A (VEGF-A) Inhibitor, Vascular Endothelial Growth Factor-B (VEGF-B) Inhibitor, Placental 1 Growth Factor (P1GF) InhibitorIntraocular

Figure: Number of Drugs for The Treatment of Retinal Vein Occlusion Under Each Stage of Development


The research process includes extensive secondary research on public domain and other authentic sources carried out to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, clinical trials registries.


The pipeline landscape report consists of pipeline product based on several stages of development ranging from discovery to Pre-Registration. The report provides a review of pipeline therapeutics for Retinal Vein Occlusion by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of Retinal Vein Occlusion therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, and key upcoming milestones.

Reasons to Buy

Helps to find and recognize significant therapeutics under development for Retinal Vein Occlusion.

Thorough understanding of Retinal Vein Occlusion pipeline structure and helps in developing corrective measures for pipeline projects.

Effective R&D strategies can be developed with deep knowledge on competitor information, analysis, and insights.

Plan of collaborations from various industry partners that have role in some or the other stage of drug development like contract manufacturing, co-development, contract research organization and commercialization etc.

Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Frequently Asked Questions
• What is Retinal Vein Occlusion?
• What are the Causes, Signs and Symptoms of Retinal Vein Occlusion?
• How is Retinal Vein Occlusion diagnosed?
• What are the most common treatments available for Retinal Vein Occlusion?
• How many/which companies are developing Retinal Vein Occlusion drugs?
• How many Retinal Vein Occlusion drugs are under development by each company and their stage of development?
• How many emerging drugs are in late-stage, mid-stage and early-stage of development for the Retinal Vein Occlusion treatment?
• What are the key collaborations, mergers and acquisitions, licensing activities related to the Retinal Vein Occlusion therapeutics?
• What are the molecule types, target, mechanism of action and route of administration of emerging drugs under development for the treatment of Retinal Vein Occlusion?
• What are the clinical studies available for Retinal Vein Occlusion and their status?
• What are the key regulatory designations that have been granted to the treatment emerging drugs?
• What are the key upcoming milestones for Retinal Vein Occlusion drugs?
• How many drugs are under Inactive or Discontinued for the treatment of Retinal Vein Occlusion?

Table of Contents

List of Tables
List of Figures

1. Introduction
1.1 Retinal Vein Occlusion – Pipeline Drugs, 2023 – Coverage

2. Disease Overview – Retinal Vein Occlusion
2.1 Causes
2.2 Signs and Symptoms
2.3 Diagnosis
2.4 Disease Management

3. Retinal Vein Occlusion – Pipeline Drugs Development – Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products under Development by Companies, 2023
3.3 Products under Development by Companies, 2023

4. Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.3 Assessment by Route of Administration

5. Drug Profiles
5.1 Clinical Stage Drugs – Phase III
5.1.1 601A
5.1.2 BA9101
5.1.3 KSI-301
5.1.4 ONS-5010
5.1.5 RG7716
5.2 Clinical Stage Drugs – Phase II
5.2.1 Human Recombinant Annexin A5 Protein (ANXV)
5.2.2 IBE-814
5.3 Clinical Stage Drugs – Phase I
5.3.1 MHU650
5.3.2 RG7921
5.4 Early-Stage Drugs – IND/CTA Filed
5.4.1 AXT107
5.5 Early-Stage Drugs – Preclinical
5.5.1 AG-73305
5.5.2 ANB-C
5.5.3 ANB-G
5.5.4 ANB-T
5.5.5 EYP-1901
5.5.6 EYS809
5.5.7 OXU-001
5.5.8 VLTR-557
5.6 Early-Stage Drugs – Discovery
5.6.1 ANB-M
5.6.2 ANB-S

6. Key Regulatory Designations

7. Key Deals

8. Key Upcoming Milestones

9. Key Companies Involved
9.1 Allgenesis Biotherapeutics Inc
9.3 Annexin Pharmaceuticals AB
9.4 AsclepiX Therapeutics Inc
9.5 EyePoint Pharmaceuticals Inc
9.6 Eyevensys SAS
9.7 Hoffmann-La Roche Ltd
9.8 Kodiak Sciences Inc
9.9 Luye Pharma Group Ltd
9.10 Novartis Pharmaceuticals
9.11 Outlook Therapeutics Inc
9.12 Oxular Ltd
9.13 Ripple Therapeutics Pty Ltd
9.14 Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd
9.15 Valitor Inc

10. Dormant Drugs
10.1 Inactive Drugs
10.2 Discontinued Drugs

11. Appendix

List of Tables
Table 1.1 Number of Products Under development for Retinal Vein Occlusion
Table 1.2 Number of Products under Development by Companies
Table 1.3 Products under Development by Companies
Table 1.4 Products by Targets
Table 1.5 Products by Mechanism of Action
Table 1.6 Products by Molecule Type
Table 1.7 Products by Route of Administration
Table 2.1 Clinical Trial Details – 601A/Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd
Table 2.2 Clinical Trial Details – KSI-301/Kodiak Sciences Inc
Table 2.3 Clinical Trial Details – ONS-5010/Outlook Therapeutics Inc
Table 2.4 Clinical Trial Details – RG7716/Hoffmann-La Roche Ltd
Table 2.5 Clinical Trial Details – Human Recombinant Annexin A5 Protein (ANXV)/Annexin Pharmaceuticals AB
Table 2.6 Clinical Trial Details – IBE-814/Ripple Therapeutics Pty Ltd
Table 2.7 Clinical Trial Details – MHU650/Novartis Pharmaceuticals
Table 3.1 Regulatory Designations
Table 4.1 Inactive Drugs

List of Figures
Figure 1.1 Number of Products under Development for Retinal Vein Occlusion, 2023
Figure 1.2 Products by Top 5 Targets and Stage of Development for Retinal Vein Occlusion, 2023
Figure 1.3 Products by Top 5 Mechanism of Action and Stage of Development for Retinal Vein Occlusion, 2023
Figure 1.4 Products by Top 5 Molecule Type and Stage of Development for Retinal Vein Occlusion, 2023
Figure 1.5 Products by Top 5 Route of Administration and Stage of Development for Retinal Vein Occlusion, 2023

Report Segmentation
  • Assessment by Stage of Development
  • Assessment by Companies
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Molecule Type
  • Assessment by Route of Administration

Order this Report

Have questions about the scope of the report ?

Have specific requirements ?

Budget Constraints ?

Related Reports

The term nutragenomics refers to the study of…
Major Depressive Disorder (MDD) also known as clinical…
Obsessive-compulsive disorder (OCD) is a common, chronic, and…
Gaucher's disease, or Gaucher disease (GD), is an…
The Empty Capsules Market is growing rapidly as…
Cell lysis is the process of breaking open…
The global Sanger Sequencing Market was valued at…
A biomarker is a measurable indicator of the…
Fibromyalgia is a is a common chronic syndrome…
Acne Vulgaris is a skin condition that occurs…